<code id='FAC8784C92'></code><style id='FAC8784C92'></style>
    • <acronym id='FAC8784C92'></acronym>
      <center id='FAC8784C92'><center id='FAC8784C92'><tfoot id='FAC8784C92'></tfoot></center><abbr id='FAC8784C92'><dir id='FAC8784C92'><tfoot id='FAC8784C92'></tfoot><noframes id='FAC8784C92'>

    • <optgroup id='FAC8784C92'><strike id='FAC8784C92'><sup id='FAC8784C92'></sup></strike><code id='FAC8784C92'></code></optgroup>
        1. <b id='FAC8784C92'><label id='FAC8784C92'><select id='FAC8784C92'><dt id='FAC8784C92'><span id='FAC8784C92'></span></dt></select></label></b><u id='FAC8784C92'></u>
          <i id='FAC8784C92'><strike id='FAC8784C92'><tt id='FAC8784C92'><pre id='FAC8784C92'></pre></tt></strike></i>

          Home / entertainment / comprehensive

          comprehensive


          comprehensive

          author:Wikipedia    Page View:99

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In